Umbrella review and network meta-analysis of diagnostic imaging test accuracy studies in Differentiating between brain tumor progression versus pseudoprogression and radionecrosis
ConclusionThe evidence regarding which imaging modality is best for the differentiation between radiation necrosis and post-treatment radiation effects is still inconclusive. Using NMA, our analysis ranked FET PET to be the best for such a task based on the available evidence. APT MRI showed promising results as a non-nuclear alternative. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 11, 2024 Category: Cancer & Oncology Source Type: research
Risk factors for glioblastoma in adults in Japan: an exploratory cohort study based on the Shizuoka Kokuho Database, the Shizuoka study
ConclusionEmploying a robust health insurance database, this study revealed significant associations between GBM and factors such as age, male sex, and PVD within the Japanese population. It provides key insights into GBM epidemiology and underscores the potential of health insurance databases for large-scale oncological research. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 11, 2024 Category: Cancer & Oncology Source Type: research
Letter: Exploring cell-free DNA as a biomarker for assessing tumor burden in metastatic spine disease
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 11, 2024 Category: Cancer & Oncology Source Type: research
Volumetric growth rate of incidentally found meningiomas on immunotherapy
ConclusionCheck-point inhibitors may impact the natural history of meningiomas. Additional research is needed to define potential clinical indications and treatment goals. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 9, 2024 Category: Cancer & Oncology Source Type: research
The role of microRNAs in brain metastasis
AbstractBrain metastasis (BM) is the most common type of brain tumor and frequently foreshadows disease progression and poor overall survival with patients having a median survival of 6 months. 70,000 new cases of BM are diagnosed each year in the United States (US) and the incidence rate for BM is increasing with improved detection. MicroRNAs (miRNAs) are small non-coding RNAs that serve as critical regulators of gene expression and can act as powerful oncogenes and tumor suppressors. MiRNAs have been heavily implicated in cancer and proposed as biomarkers or therapeutic targets or agents. In this review, we summarize an ...
Source: Journal of Neuro-Oncology - January 9, 2024 Category: Cancer & Oncology Source Type: research
Endosome associated trafficking regulator 1 promotes tumor growth and invasion of glioblastoma multiforme via inhibiting TNF signaling pathway
ConclusionOur results indicated that ENTR1 played an important role in cell proliferation, invasion and chemotherapeutic sensitivity of GBM, suggesting that ENTR1 might be a novel prognostic marker and significant therapeutic target for GBM. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 8, 2024 Category: Cancer & Oncology Source Type: research
Multi-omics analyses of choroid plexus carcinoma cell lines reveal potential targetable pathways and alterations
ConclusionMulti-omics analyses revealed that the two choroid plexus carcinoma cell lines sharedTP53 mutations and other common pathway alterations and activation of NOTCH and WNT pathways. Noticeable differences were also observed. These cell lines can serve as valuable models to propose new treatments in these rare but deadly brain tumors. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 8, 2024 Category: Cancer & Oncology Source Type: research
Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells
ConclusionOur study identifies the combination of class I HDACi and BCL-XL inhibitors as a potential new approach for the treatment ofMYC-amplified MB cells.Graphical abstractGraphical abstract created with BioRender.com, illustrating the workflow and summarizing main results. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 7, 2024 Category: Cancer & Oncology Source Type: research
Understanding current experimental models of glioblastoma-brain microenvironment interactions
AbstractGlioblastoma (GBM) is a common and devastating primary brain tumor, with median survival of 16 –18 months after diagnosis in the setting of substantial resistance to standard-of-care and inevitable tumor recurrence. Recent work has implicated the brain microenvironment as being critical for GBM proliferation, invasion, and resistance to treatment. GBM does not operate in isolation, with neu rons, astrocytes, and multiple immune populations being implicated in GBM tumor progression and invasiveness. The goal of this review article is to provide an overview of the available in vitro, ex vivo, and in vivo experiment...
Source: Journal of Neuro-Oncology - January 5, 2024 Category: Cancer & Oncology Source Type: research
Treatment outcomes of single-fraction stereotactic radiosurgery for adenoid cystic carcinoma: a case series of 55 patients
ConclusionSRS provided a high rate of local tumor control, but marginal failure was frequent. Integrating SRS with added EBRT exhibits potential for enhancing local and local/marginal tumor control, particularly in recurrent cases. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 5, 2024 Category: Cancer & Oncology Source Type: research
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
ConclusionThis study demonstrates that the combined use of bevacizumab with concurrent stereotactic radiosurgery can have improve survival in patients with rGBM. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 4, 2024 Category: Cancer & Oncology Source Type: research
The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment
ConclusionThe ASL-derived rCBF values of recurrent lesions may serve as an effective imaging biomarker for prognosis in HGG patients undergoing BVZ therapy. Low rCBF values may indicate that BVZ efficacy is sustainable, which will influence BVZ treatment strategies in HGG patients. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 2, 2024 Category: Cancer & Oncology Source Type: research
Comparative evaluation of 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography for distinguishing between primary central nervous system lymphoma and isocitrate dehydrogenase-wildtype glioblastoma
ConclusionMET PET could detect both PCNSL and IDH-wildtype glioblastoma, but unlike FDG PET, it could not distinguish between these two major malignant brain tumors. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - December 31, 2023 Category: Cancer & Oncology Source Type: research
Rapid detection of mutations in CSF-cfTNA with the Genexus Integrated Sequencer
ConclusionIn summary, our results indicate that CSF-cfTNA analysis with the Genexus-OPA can provide clinically relevant information in patients with brain metastases with short TAT. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - December 30, 2023 Category: Cancer & Oncology Source Type: research
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
ConclusionFor glioblastoma patients, extending post-radiation temozolomide from 6 to 12 months is well tolerated but does not improve 6mPFS. We could not identify any subset that benefitted from extended treatment. Six months should remain standard-of-care. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - December 28, 2023 Category: Cancer & Oncology Source Type: research
